Because phosphodiesterase (PDE) expression and activity are controlled by cAMP, we investigated whether activating mutations of Gs␣ gene that occur in human GH-secreting adenomas are associated with increased PDE activity. We studied 10 adenomas with wild-type Gs␣ (gspϪ) and 8 with mutant Gs␣ (gspϩ). Although, in the absence of PDE inhibitors, intracellular cAMP levels were similar in gspϩ e gspϪ adenomas, the PDE blockade with 3-isobutyl-1-methylxanthine induced a marked increase in cAMP in all but one gspϩ adenoma (% increase: from 77 to 2900) and a slight rise in only 2 gspϪ. Similar results were obtained with the PDE4 selective inhibitor 4-[3-(cyclopentyloxy)-4-methoxyphenyl]-2-pyrrolidinone. In vitro GH release was significantly higher in gspϩ than in gspϪ adenomas (315 Ϯ 158 vs. 82 Ϯ 53 g/well; P Ͻ 0.01), and PDE blockade caused a further increase in 3 of 5 gspϩ adenomas but not in gspϪ tumors. By direct measurement, PDE activity was about 7-fold higher in gspϩ than in gspϪ adenomas (320 Ϯ 213 vs. 48 Ϯ 23 pmol/min⅐mg protein; P Ͻ 0.05) and was largely 4-[3-(cyclopentyloxy)-4-methoxyphenyl]-2-pyrrolidinone sensitive. This study first demonstrates that activating mutations of the Gs␣ gene that naturally occur in pituitary adenomas is associated with an increased PDE activity that might, at least partially, counteract the constitutive activation of the cAMP-dependent pathway. (J Clin Endocrinol Metab 83: 1624 -1628, 1998) 
I
T IS well established that cAMP controls metabolic and differentiation processes in almost all endocrine cells. Moreover, the identification of activating mutations of the adenylyl cyclase stimulatory protein Gs␣, or Gs-coupled receptor genes, in human hyperfunctioning tissues strongly suggests a proliferative action of cAMP in selected cell types, such as somatotrophs and thyrocytes (1) (2) (3) (4) (5) (6) (7) (8) . Intracellular cAMP levels depend on the activity of adenylyl cyclase and cyclic nucleotide phosphodiesterase (PDE), a given cAMP concentration being the result of a steady state of synthesis and degradation. Inactivation of cyclic nucleotides is catalyzed by a large number of different PDE isoenzymes, belonging to at least seven families (9, 10) .
The PDE activity is finely regulated by the modification of intracellular cAMP levels. In particular, increased cAMP levels induce a short-term activation of cAMP specific-PDEs (PDE4) via a series of phosphorylation processes and a longterm activation via gene expression and protein synthesis regulation (9 -12) . Moreover, it has been recently reported that the feedback mechanism by which cAMP controls the expression of its own degrading enzymes is overactive in the presence of the cAMP pathway that is abnormally stimulated (13) . In fact, the PDE-mediated cAMP hydrolysis was demonstrated to be dramatically increased in FRTL-5 cells expressing a mutated Gs␣, conferring constitutive activation to adenylyl cyclase (13) .
It is widely accepted that about 30% of human GH-secreting pituitary adenomas carry gain of function mutations of the Gs␣ gene that cause constitutive activation of adenylyl cyclase (3, 4, 14 -17) . Because the cAMP pathway is involved in somatotroph replication (18) , it has been proposed that the Gs␣ gene may be converted into an oncogene, designated gsp (for Gs protein), in selected cell types (4, 6) . The in vitro phenotype of somatotrophs that express these mutations is consistent with the constitutive activation of Gs protein, because it is characterized by high adenylyl cyclase activity that is not further stimulated by any agents, resulting in in vitro GH hypersecretion (3) . In contrast, no significant differences in the in vivo phenotype of acromegalic patients, bearing adenomas with or without Gs␣ mutations, have been reported so far, suggesting the existence of regulatory mechanisms able to counteract the effects of cAMP activation in these tumors (14 -17) . The aim of the study was to investigate whether the activation of the cAMP-dependent pathway caused by Gs␣ mutations is associated with an increase in PDE activity in human GH-secreting adenomas.
Subjects and Methods

Patients and tumors
Eighteen tumors, surgically removed by the transsphenoidal route from patients affected with acromegaly, were included in this study (Table 1) . Acromegaly was diagnosed on the basis of clinical features, elevated insulin-like growth factor-I plasma levels, and elevated GH levels not suppressible during oral glucose tolerance test. No patient had previously undergone pituitary irradiation. Small adenoma fragments were fixed, for light and electron microscopy, to check the adenomatous nature of the material, as previously described (19) . Part of the tissue was quickly frozen for Gs␣ gene analysis and PDE activity assay, and part was placed in sterile culture medium for cell culture. Local ethical approval was obtained for all studies.
Analysis of mutations in Gs␣ gene
DNA was obtained from tissue homogenates by acid guanidine thiocyanate-phenol-chloroform extraction (20) . After DNA extraction, gene amplifications were performed by PCR technique. Briefly, 100 ng DNA were amplified in a 50-L reaction mixture containing 2 U Taq DNA sequencing was carried out using the thermo sequenase radiolabeled terminator cycle sequencing kit (Amersham, Little Chalfont, UK).
Cell culture
Cells were enzymatically dispersed using trypsin and deoxyribonuclease, as previously described (21) . The suspension obtained consisted largely of single cells with a viability (as assessed by trypan blue exclusion) greater than 90%. The dispersed cells were plated at a density of 2 ϫ 10 5 cells/mL, in 24-well plastic cluster dishes, and cultured in DMEM supplemented with 10% FCS and antibiotics at 37 C, in an atmosphere of 95% air-5% CO 2 , in a humidified incubator. After 3-4 days, culture medium was removed by aspiration, and the cell monolayers were washed twice and preincubated for 1 h with HBSS supplemented with 0.1% BSA. Cells were then incubated for 1 h in fresh medium, in the absence or presence of either 500 mol/L 3-isobutyl-1-methylxanthine (IBMX) or 50 mol/L 4-[3-(cyclopentyloxy)-4-methoxyphenyl]-2-pyrrolidinone (rolipram) at 37 C, in triplicate. At the end of the incubation, the medium was removed and stored at Ϫ20 C until GH assay, while cell monolayers were treated for intracellular cAMP extraction and measurement. GH was measured in cell culture supernatants, by an immunofluorimetric assay using a commercial kit (Pharmacia, Turku, Finland).
Intracellular cAMP assay
Intracellular cAMP levels were measured as previously described (22) . Briefly, after the removal of the incubation medium, cells were washed with HBSS and 0.1% BSA, and then 1 mL ice-cold ethanol (80%) was added. After remaining at Ϫ20 C overnight, samples were harvested, transferred to polyethylene tubes, and centrifuged at 180 ϫ g for 5 min at 4 C. The supernatants were then evaporated to dryness and redissolved in cAMP kit buffer (0.5 mL). cAMP was measured without acetylation, using an enzyme immunoassay commercial kit (Amersham). The minimum detection limit was approximately 0.12 pmol/mL for nonacetylated samples; cross-reaction with cGMP was less than 0.001%. The intra-and interassay coefficients of variation were Ͻ7% and Ͻ10%, respectively.
PDE activity assay
For PDE activity assay, the adenoma tissues were frozen immediately after surgery and stored up to 10 days at Ϫ80 C. Tissue homogenization was performed using a glass-Teflon Potter homogenizer in a buffer containing 20 mmol/L Tris-HCl (pH 8.0), 1 mmol/L EDTA, 0.2 mmol/L EGTA, 10 mmol/L sodium pyrophosphate, 50 mmol/L benzamidine, 0.5 g/mL leupeptin, 0.7 g/mL pepstatin, 4 g/mL aprotinin, 10 g/mL soybean trypsin inhibitor, and 2 mmol/L phenylmethylsulfonylfluoride. PDE assay was carried out on membrane preparations sedimented from the homogenates by centrifugation at 40,000 ϫ g for 30 min and resuspended in the buffer. In some experiments, both the pellet and the supernatant were tested for PDE activity, giving similar results (data not shown). Protein measurement was performed using the bicinchoninic protein assay. PDE assay was carried out using 1 mol/L cAMP as substrate, according to the method of Thompson and Appleman (23) . Samples were assayed in a total vol of 200 L reaction mixture containing 40 mmol/L Tris-HCl (pH 8.0), 10 mmol/L MgCl 2 , 1.25 mmol/L 2-mercaptoethanol, 0.15 mg BSA, 1 mol/L unlabeled cAMP, and 0.1 Ci [
3 H]cAMP. Triplicate samples were incubated at 34 C for 10 min, and the reaction was stopped by heat denaturation for 1 min at 100 C. To convert AMP to adenosine, 50 g Crotalus atrox snake venom were added to each sample, and the reaction was carried out for 15 min at 34 C. The formed adenosine was separated by Dowex resin and an aliquot of unbound [ 3 H] adenosine was added to scintillation fluid for counting. The inclusion of ethanol in the resin did not modify PDE activity values. The intra-and interassay coefficients of variation were Ͻ7% and Ͻ15%, respectively. For the inhibitor studies, samples were incubated in the presence of rolipram or IBMX at the maximal effective concentrations.
Reagents
Culture media, Crotalus atrox snake venom, leupeptin, pepstatin, aprotinin, trypsin, soybean trypsin inhibitor, and IBMX were purchased from Sigma (St. Louis, MO). [2,8- 3 H] cAMP (20 -50 Ci/mmol) was purchased from DuPont NEN (Boston, MA). Dowex 1 ϫ 8 resin was purchased from Fluka (Buchs, Switzerland), and rolipram was purchased from ICN Pharmaceuticals (Costa Mesa, CA). TRI-REAGENT was from Molecular Research Center (Cincinnati, OH). All other chemicals were reagent grade. intra extra extra extra intra extra intra extra extra intra intra extra intra intra extra intra extra intra 
Statistical analyses
The results are expressed as the mean Ϯ sd. Paired or unpaired two-tailed Student's t test was used to detect the significance between two series of data. P Ͻ 0.05 was accepted as statistically significant.
Results
Analysis of mutations in the Gs␣ gene
Eighteen GH-secreting adenomas were submitted to mutation analysis. Eight tumors (35.7%) were found to harbor point mutations of Gs␣ gene as follows: 6 at codon 201 (CGTϾTGT/ArgϾCys in tumors no. 11, 12, 14, 17, and 18; and CGTϾAGT/ArgϾSer in no. 13) and 2 at codon 227 (CAGϾCGG/GlnϾArg in tumors no. 15 and 16) and were defined as gspϩ. All mutations reported here are known to constitutively activate adenylyl cyclase. No significant difference in tumor size and serum GH levels (13. 6 Ϯ 9.2 g/L in gspϪ vs. 16.7 Ϯ 13.5 in gspϩ; P, not significant) between patients, with or without Gs␣ mutations, was observed.
Effect of PDE inhibitors on intracellular cAMP levels
Despite the presence of activating mutations of the Gs␣ gene, cells obtained from seven of eight gspϩ tumors showed basal intracellular cAMP levels similar to those obtained from tumors with wild-type Gs␣ (gspϪ) (6.5 Ϯ 7.3 pmol/well in gspϩ vs. 3.5 Ϯ 3.7 pmol/well in gspϪ; P, not significant), whereas only 1 gspϩ adenoma (no. 16) had very high basal cAMP levels (22.1 Ϯ 2.0 pmol/well) (Fig. 1) .
The effect of PDE blockade on intracellular cAMP accumulation was investigated by using a nonselective PDE inhibitor (IBMX) and a PDE4-selective inhibitor (rolipram) at the maximal effective concentrations. In 8 of 10 gspϪ tumors, neither IBMX (500 mol/L) nor rolipram (50 mol/L) affected cAMP levels. In 2 gspϪ adenomas ( nos. 5 and 7), the incubation with IBMX caused a significant (but slight) increase in cAMP accumulation, whereas rolipram was ineffective (Fig 1a) . In contrast, in gspϩ tumors, the blockade of PDE activity resulted in a marked stimulation of intracellular cAMP accumulation, the increase induced by IBMX ranging from 77-2900%. Similar results were obtained by incubating cells with rolipram (Fig. 1b) . Interestingly, the only gspϩ tumor with very high cAMP levels in basal conditions showed a poor response to PDE inhibition (22% increase by IBMX and 17% by rolipram) (Fig. 1b) .
Effect of PDE inhibitors on in vitro GH release
The effect of PDE inhibitors on in vitro GH release was evaluated in 11 adenomas (6 gspϪ and 5 gspϩ). Contrary to results observed when measuring intracellular cAMP levels, in vitro GH release from cells expressing mutant Gs␣ was markedly higher than that from cells with wild-type Gs␣ (315 Ϯ 158 vs. 82 Ϯ 53 g/well; P Ͻ 0.01), in the absence of PDE inhibitors. As far as the PDE blockade was concerned, neither IBMX nor rolipram was effective in increasing GH release in gspϪ tumors (Fig. 2, and data not shown) . In contrast, in 3 of 5 gspϩ tumors, the incubation with both PDE inhibitors induced a significant increase in GH levels (Fig. 2) .
PDE activity in gspϩ and gspϪ tumors
PDE activity was measured in 6 gspϪ and 5 gspϩ tumors. The enzyme activity, though variable from one tumor to another, was about 7-fold higher in gspϩ than in gspϪ GHsecreting adenomas (320 Ϯ 213 vs. 48 Ϯ 23 pmol/min⅐mg protein; P Ͻ 0.05) (Fig. 3) . Because of the small size of pituitary adenomatous tissues, it was not possible to measure PDE activity in all tumors (in particular, tumor no. 16, which was the only gspϩ tumor with cAMP levels poorly affected by IBMX). To further characterize the properties of the PDE activated in cells expressing Gs␣ mutations, the PDE activity was measured in the presence of the nonselective PDE inhibitor (IBMX) and the PDE4-selective inhibitor (rolipram). The increase in basal PDE activity that was observed in gspϩ tumors was caused, in large part, by rolipram-sensitive PDE isoforms, given that 64% of the activity was abolished by rolipram (Fig. 4) . In contrast, in gspϪ cells, only 28% of the PDE activity was inhibited by the PDE4-selective inhibitor (Fig. 4) .
Discussion
These data first demonstrate that activating mutations of the Gs␣ gene, naturally occurring in human GH-secreting pituitary adenomas, are associated with increased PDE ac- tivity. Both the modifications of cAMP levels induced by PDE inhibitors in intact cells and the direct measurement of the enzyme activity in tumoral tissues point to a marked difference of tumors, with and without Gs␣ mutations, in the rate of cAMP degradation. In fact, inhibition of PDE activity resulted in a marked increase in cAMP accumulation in cells from gspϩ tumors, whereas the effect was little, if any, in gspϪ cells. These data were consistent with the existence of high PDE activity in cells with constitutive activation of the cAMP-dependent pathway, that was confirmed by direct measurement. Although the small size of pituitary adenomatous tissues made PDE assay feasible only in a limited number of tumors, the PDE activity measured in gspϩ tumors was about 7-fold higher than that observed in wild-type tumors. Because the difference between these tumor subtypes is the presence of constitutive activation of adenylyl cyclase, it is most likely that increased PDE activity in gspϩ tumors is dependent on increased cAMP production, suggesting that, in these tumors, the feedback loop by which the activation of the cAMP-dependent pathway increases the rate of cAMP hydrolysis is operating. The lack of normal human pituitary as control makes it impossible to determine whether the low PDE activity observed in tumors with wildtype Gs␣ is related to the tumoral nature of the tissues or is characteristic of the somatotroph cell type. Moreover, data on the expression of PDE isoforms in rat pituitary and pituitary cell lines are scarce and contradictory (24, 25) .
In gspϩ tumors, the high PDE activity was caused largely by increased activity of the cAMP-specific, rolipram-sensitive, cAMP-PDE (PDE4). In fact, rolipram, a selective PDE4 inhibitor, was nearly as effective as IBMX, a nonselective PDE inhibitor, in stimulating cAMP accumulation in intact cells and blocking the enzyme activity in membrane preparations. The involvement of isoenzymes of the PDE4 family in the feedback mechanism activated by the cAMP pathway in gspϩ GH-secreting adenomas is consistent with the pattern of PDE4 regulation. In fact, the activation of Gs-coupled receptors, as well as the increase of cAMP levels induced by cholera toxin or forskolin, seems to selectively increase PDE4 activity (11, 12) . From our study, it is not possible to distinguish whether the increase in PDE4 activity is caused by an activation or an increased expression of the enzyme. However, it is reasonable to hypothesize that the long-term adaptation of somatotrophs that express mutant Gs␣ to the constitutively activated cAMP-dependent pathway might require both enzyme activation and increased gene expression.
The increased PDE activity had a major impact on the in vitro phenotype of somatotrophs expressing mutant Gs␣. In fact, although substitutions at either codon 201 or 227 in Gs␣ gene are known to constitutively stimulate adenylyl cyclase by inhibiting the intrinsic GTPase activity (17) , no difference in cAMP levels was observed in adenomatous somatotrophs, with and without Gs␣ mutations, unless PDE inhibitors were added to the cells. In this respect, it is worth noting that the only gspϩ tumor in which PDE blockade was ineffective in increasing cAMP accumulation was characterized by extremely high cAMP levels in basal conditions. Therefore, it is most likely that the high cAMP levels in gspϩ tumors previously reported might be caused by the routine inclusion of PDE inhibitors in the incubation buffer used to study cAMP production (3) .
Although the activation of the PDE feedback loop seems to counteract the ability of Gs␣ mutations to constitutively stimulate cAMP levels, the phenotype of mutant Gs␣ was characterized by an in vitro GH release that was definitely higher than that observed in wild-type tumors. It is possible to hypothesize that small differences in cAMP levels might result in significant differences in biological responses, such as GH secretion. These data suggest that mutant Gs␣ phenotype may be reverted only in part by the increased PDE activity, and they further strengthen the view that multiple processes contribute to determine the oncogenic potential of activating mutations of Gs␣ in the different cell types. Moreover, the observation that (contrary to the results observed in vitro) serum GH levels in patients with and without gsp oncogene did not differ significantly, points to an involvement of central inhibitory influences in determining the in vivo phenotype.
The data obtained in tumoral somatotrophs are consistent with those obtained in mammalian cells transfected with mutant Gs␣ (13, 26, 27) . In particular, it has been reported that FRTL-5 thyroid cells expressing the Gln227Leu mutation of Gs␣ are characterized by an increased PDE activity, the blockade of PDE4 resulting in a further stimulation of cAMP levels and cell proliferation (13) . Moreover, it has been reported that Swiss 3T3 fibroblasts expressing mutated Gs␣ had mitogenic activity only in the presence of PDE4 inhibitors (26) . In contrast, GH3 cells expressing the same mutation showed a high proliferation rate, even in the absence of PDE blockade (27) .
To the best of our knowledge, this is the first demonstration that mutations of the Gs␣ gene that naturally occur in pituitary tumors are followed by an increase in PDE activity in vivo. Although other mechanisms may be involved in determining the in vivo phenotype of patients bearing gspϩ tumors, such as the high sensitivity of these patients to the inhibitory action of somatostatin (6, 14) , it is most likely that the increased degradation of cAMP caused by PDE overactivity may, at least in part, contrast the consequence of the constitutive activation of the cAMP-dependent pathway. It remains to be elucidated whether the PDE feedback loop is also activated in other endocrine disorders caused by mutations in Gs␣, such as thyroid toxic adenomas and the McCune-Albright syndrome (8, 28) .
